Search
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
LY-517717
go.drugbank.com/drugs/DB05713InvestigationalLY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
Pargyline
go.drugbank.com/drugs/DB01626ApprovedPargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Danegaptide
go.drugbank.com/drugs/DB11821InvestigationalDanegaptide has been investigated for the treatment of Focus of Study is STEMI.
Resiniferatoxin
go.drugbank.com/drugs/DB06515InvestigationalResiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission
Diosmetin
go.drugbank.com/drugs/DB11259ApprovedDiosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231]. … Pharmacologically, diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic and anti-inflamatory activities [A27231]. It also acts as a weak TrkB receptor agonist [A27230].
Sulfaguanidine
go.drugbank.com/drugs/DB13726ExperimentalSulfaguanidine is a sulfonamide antibiotic with antimicrobial and antibacterial activities.[A275108]
Canfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Biapenem
go.drugbank.com/drugs/DB13028InvestigationalIt is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008] … Biapenem has been used in trials studying the treatment of various bacterial infections.
Glypromate
go.drugbank.com/drugs/DB05633ExperimentalIn December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by IV